Livanova Plc (LIVN)

$44.85

-0.02

(-0.04%)▲

Market is closed - opens 8 PM, 01 Dec 2023

Insights on Livanova Plc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 293.9M → 286.1M (in $), with an average decrease of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 7.4M → -7.3M (in $), with an average decrease of 396.1% per quarter

  • Vs SYK

    In the last 1 year, Stryker Corporation has given 23.1% return, outperforming this stock by 43.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 28.3% return, outperforming this stock by 42.5%

Performance

  • $44.72
    $45.87
    $44.85
    downward going graph

    0.3%

    Downside

    Day's Volatility :2.52%

    Upside

    2.22%

    downward going graph
  • $40.26
    $59.86
    $44.85
    downward going graph

    10.23%

    Downside

    52 Weeks Volatility :32.74%

    Upside

    25.08%

    downward going graph

Returns

PeriodLivanova PlcSector (Health Care)Index (Russel 2000)
3 Months
-19.7%
-1.7%
0.0%
6 Months
-1.64%
2.1%
0.0%
1 Year
-20.14%
-5.8%
-6.0%
3 Years
-14.16%
18.7%
-3.7%

Highlights

Market Capitalization
2.4B
Book Value
$22.75
Dividend Share
0.0
Dividend Yield
2.34%
Earnings Per Share (EPS)
0.05
PE Ratio
882.4
PEG Ratio
5.02
Wall Street Target Price
61.89
Profit Margin
0.26%
Operating Margin TTM
1.56%
Return On Assets TTM
1.74%
Return On Equity TTM
0.24%
Revenue TTM
1.1B
Revenue Per Share TTM
20.81
Quarterly Revenue Growth YOY
13.3%
Gross Profit TTM
696.7M
EBITDA
113.0M
Diluted Eps TTM
0.05
Quarterly Earnings Growth YOY
-0.93
EPS Estimate Current Year
2.7
EPS Estimate Next Year
3.03
EPS Estimate Current Quarter
0.64
EPS Estimate Next Quarter
0.82

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Livanova Plc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
5
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 37.99%

Current $44.85
Target $61.89

Company Financials

FY17Y/Y Change
Revenue
1.0B
↓ 16.61%
Net Income
-25.1M
↓ 60.03%
Net Profit Margin
-2.48%
↑ 2.69%
FY18Y/Y Change
Revenue
1.1B
↑ 9.35%
Net Income
-189.4M
↑ 654.58%
Net Profit Margin
-17.11%
↓ 14.63%
FY19Y/Y Change
Revenue
1.1B
↓ 2.06%
Net Income
-155.5M
↓ 17.9%
Net Profit Margin
-14.34%
↑ 2.77%
FY20Y/Y Change
Revenue
934.2M
↓ 13.84%
Net Income
-343.3M
↑ 120.77%
Net Profit Margin
-36.75%
↓ 22.41%
FY21Y/Y Change
Revenue
1.0B
↑ 10.83%
Net Income
-135.7M
↓ 60.47%
Net Profit Margin
-13.11%
↑ 23.64%
FY22Y/Y Change
Revenue
1.0B
↓ 1.31%
Net Income
-86.2M
↓ 36.48%
Net Profit Margin
-8.44%
↑ 4.67%
Q2 FY22Q/Q Change
Revenue
254.2M
↑ 5.84%
Net Income
16.4M
↑ 447.95%
Net Profit Margin
6.45%
↑ 5.2%
Q3 FY22Q/Q Change
Revenue
252.6M
↓ 0.63%
Net Income
-107.4M
↓ 754.88%
Net Profit Margin
-42.52%
↓ 48.97%
Q4 FY22Q/Q Change
Revenue
274.9M
↑ 8.83%
Net Income
1.7M
↓ 101.58%
Net Profit Margin
0.62%
↑ 43.14%
Q1 FY23Q/Q Change
Revenue
263.4M
↓ 4.18%
Net Income
7.4M
↑ 335.29%
Net Profit Margin
2.81%
↑ 2.19%
Q2 FY23Q/Q Change
Revenue
293.9M
↑ 11.58%
Net Income
1.2M
↓ 83.78%
Net Profit Margin
0.41%
↓ 2.4%
Q3 FY23Q/Q Change
Revenue
286.1M
↓ 2.65%
Net Income
-7.3M
↓ 708.33%
Net Profit Margin
-2.55%
↓ 2.96%
FY17Y/Y Change
Total Assets
2.5B
↑ 6.89%
Total Liabilities
688.6M
↑ 8.32%
FY18Y/Y Change
Total Assets
2.5B
↑ 1.83%
Total Liabilities
1.0B
↑ 51.9%
FY19Y/Y Change
Total Assets
2.4B
↓ 5.41%
Total Liabilities
1.0B
↓ 1.71%
FY20Y/Y Change
Total Assets
2.4B
↓ 0.02%
Total Liabilities
1.3B
↑ 25.73%
FY21Y/Y Change
Total Assets
2.2B
↓ 8.73%
Total Liabilities
906.4M
↓ 29.88%
FY22Y/Y Change
Total Assets
2.3B
↑ 4.26%
Total Liabilities
1.1B
↑ 19.95%
Q2 FY22Q/Q Change
Total Assets
2.3B
↓ 3.34%
Total Liabilities
1.1B
↓ 6.3%
Q3 FY22Q/Q Change
Total Assets
2.2B
↓ 5.28%
Total Liabilities
1.1B
↑ 1.11%
Q4 FY22Q/Q Change
Total Assets
2.3B
↑ 3.7%
Total Liabilities
1.1B
↑ 2.0%
Q1 FY23Q/Q Change
Total Assets
2.3B
↑ 0.0%
Total Liabilities
1.1B
↓ 1.8%
Q2 FY23Q/Q Change
Total Assets
2.3B
↑ 2.03%
Total Liabilities
1.1B
↑ 3.13%
Q3 FY23Q/Q Change
Total Assets
2.3B
↓ 0.52%
Total Liabilities
1.1B
↑ 0.26%
FY17Y/Y Change
Operating Cash Flow
91.3M
↑ 1.22%
Investing Cash Flow
-52.9M
↑ 18.73%
Financing Cash Flow
11.3M
↓ 109.09%
FY18Y/Y Change
Operating Cash Flow
120.5M
↑ 31.98%
Investing Cash Flow
-120.6M
↑ 128.09%
Financing Cash Flow
-42.3M
↓ 474.34%
FY19Y/Y Change
Operating Cash Flow
-91.1M
↓ 175.6%
Investing Cash Flow
-41.3M
↓ 65.75%
Financing Cash Flow
146.6M
↓ 446.57%
FY20Y/Y Change
Operating Cash Flow
-79.4M
↓ 12.84%
Investing Cash Flow
-41.8M
↑ 1.34%
Financing Cash Flow
310.8M
↑ 112.01%
FY21Y/Y Change
Operating Cash Flow
102.5M
↓ 229.09%
Investing Cash Flow
36.9M
↓ 188.18%
Financing Cash Flow
-181.5M
↓ 158.4%
Q2 FY22Q/Q Change
Operating Cash Flow
-10.2M
↓ 139.59%
Investing Cash Flow
-16.1M
↑ 194.02%
Financing Cash Flow
-6.3M
↓ 102.92%
Q3 FY22Q/Q Change
Operating Cash Flow
35.6M
↓ 448.61%
Investing Cash Flow
-5.8M
↓ 63.82%
Financing Cash Flow
73.2M
↓ 1266.64%
Q1 FY23Q/Q Change
Operating Cash Flow
20.8M
↑ 11.34%
Investing Cash Flow
-11.5M
-
Financing Cash Flow
-5.2M
↑ 208.24%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.0M
↓ 186.54%
Investing Cash Flow
-6.7M
↓ 42.05%
Financing Cash Flow
36.0M
↓ 792.31%

Technicals Summary

Sell

Neutral

Buy

Livanova Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Livanova Plc
Livanova Plc
-10.37%
-1.64%
-20.14%
-14.16%
-56.17%
Stryker Corporation
Stryker Corporation
8.92%
6.38%
23.08%
28.28%
70.41%
Dexcom, Inc.
Dexcom, Inc.
22.72%
-3.4%
-2.13%
41.0%
238.3%
Boston Scientific Corp.
Boston Scientific Corp.
8.19%
8.52%
21.18%
66.09%
45.13%
Abbott Laboratories
Abbott Laboratories
9.77%
1.43%
-3.37%
-3.87%
40.42%
Medtronic Plc
Medtronic Plc
11.88%
-4.21%
0.03%
-29.31%
-19.73%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Livanova Plc
Livanova Plc
882.4
882.4
5.02
2.7
0.0
0.02
0.02
22.75
Stryker Corporation
Stryker Corporation
43.5
43.5
2.85
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
124.12
124.12
11.34
1.42
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
67.84
67.84
2.53
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
34.99
34.99
18.76
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.64
25.64
3.04
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Livanova Plc
Livanova Plc
Buy
$2.4B
-56.17%
882.4
0.26%
Stryker Corporation
Stryker Corporation
Buy
$111.6B
70.41%
43.5
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$43.1B
238.3%
124.12
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$81.5B
45.13%
67.84
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$178.6B
40.42%
34.99
12.92%
Medtronic Plc
Medtronic Plc
Buy
$105.1B
-19.73%
25.64
12.84%

Institutional Holdings

  • BlackRock Inc

    13.32%

  • PRIMECAP Management Company

    10.74%

  • Barrow Hanley Mewhinney & Strauss LLC

    4.31%

  • Millennium Management LLC

    3.65%

  • State Street Corporation

    3.62%

  • Vanguard Group Inc

    3.29%

Company Information

livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.

Organization
Livanova Plc
Employees
2900
CEO
Mr. Damien McDonald
Industry
Health Technology

Discover More

FAQs